Gioacchino D De Sario Velasquez

Dr. Gioacchino D De Sario Velasquez

Reconstructive Surgery, Houston Methodist, Houston, Texas, USA
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2023 in Bioengineering
Verified
Journal Article
Open access
PDF file
GVGioacchino D De Sario Velasquez
Gioacchino D De Sario Velasquez
CHClifton Haider
Clifton Haider
KMKarla C. Maita
Karla C. Maita
RTRicardo A Torres-Guzman
Ricardo A Torres-Guzman
OEOmar S. Emam
Omar S. Emam
Antonio Jorge ForteAntonio Jorge Forte
Antonio Jorge Forte
Pain assessment is a complex task largely dependent on the patient’s self-report. Artificial intelligence (AI) has emerged as a promising tool for automating and objectifying pain assessment through the identification of pain-related facial expressions. However, the capabilities and potential of AI in clinical settings are still largely unknown to many medical professionals. In this literature review, we present a conceptual understanding of the application of AI to detect pain through facial expressions. We provide an overview of the current state of the art as well as the technical foundations of AI/ML techniques used in pain detection. We highlight the ethical challenges and the limitations associated with the use of AI in pain detection, such as the scarcity of databases, confounding factors, and medical conditions that affect the shape and mobility of the face. The review also highlights the potential impact of AI on pain assessment in clinical practice and lays the groundwork for further study in this area.

14 May 2024 in Mayo Clinic Proceedings: Digital Health
Verified
Journal Article
Open access
GVGioacchino D De Sario Velasquez
Gioacchino D De Sario Velasquez
SBSahar Borna
Sahar Borna
MMMichael J Maniaci
Michael J Maniaci
JCJordan D. Coffey
Jordan D. Coffey
CHClifton Haider
Clifton Haider
Antonio Jorge ForteAntonio Jorge Forte
Antonio Jorge Forte
The objective of this study is to explore the current state of research concerning the cost-effectiveness of wearable health technologies, excluding hearing aids, owing to extensive previous investigation. A systematic review was performed using PubMed, EMBASE/MEDLINE, Google Scholar, and Cumulated Index to Nursing and Allied Health Literature to search studies evaluating the cost-effectiveness of wearable health devices in terms of quality-adjusted life years and incremental cost-effectiveness ratio. The search was conducted on March 28, 2023, and the date of publication did not limit the search. The search yielded 10 studies eligible for inclusion. These studies, published between 2012 and 2023, spanned various locations globally. The studies used data from hypothetical cohorts, existing research, randomized controlled trials, and meta-analyses. They covered a diverse range of wearable technologies applied in different health care settings, including respiratory rate monitors, pedometers, fall-prediction devices, hospital-acquired pressure injury prevention monitors, seizure detection devices, heart rate monitors, insulin therapy sensors, and wearable cardioverter defibrillators. The time horizons in the cost-effectiveness analyses ranged from less than a year to a lifetime. The studies indicate that wearable technologies can increase quality-adjusted life years and be cost-effective and potentially cost-saving. However, the cost-effectiveness depends on various factors, such as the type of device, the health condition being addressed, the specific perspective of the health economic analysis, local cost and payment structure, and willingness-to-pay thresholds. The use of wearables in health care promises improving outcomes and resource allocation. However, more research is needed to fully understand the long-term benefits and to strengthen the evidence base for health care providers, policymakers, and patients.

21 April 2023 in Bioengineering
Verified
Journal Article
Open access
PDF file
SBSahar Borna
Sahar Borna
CHClifton Haider
Clifton Haider
KMKarla C. Maita
Karla C. Maita
RTRicardo A Torres-Guzman
Ricardo A Torres-Guzman
FVFrancisco Rafael Avila Verduzco
Francisco Rafael Avila Verduzco
Antonio Jorge ForteAntonio Jorge Forte
Antonio Jorge Forte
Pain is a complex and subjective experience, and traditional methods of pain assessment can be limited by factors such as self-report bias and observer variability. Voice is frequently used to evaluate pain, occasionally in conjunction with other behaviors such as facial gestures. Compared to facial emotions, there is less available evidence linking pain with voice. This literature review synthesizes the current state of research on the use of voice recognition and voice analysis for pain detection in adults, with a specific focus on the role of artificial intelligence (AI) and machine learning (ML) techniques. We describe the previous works on pain recognition using voice and highlight the different approaches to voice as a tool for pain detection, such as a human effect or biosignal. Overall, studies have shown that AI-based voice analysis can be an effective tool for pain detection in adult patients with various types of pain, including chronic and acute pain. We highlight the high accuracy of the ML-based approaches used in studies and their limitations in terms of generalizability due to factors such as the nature of the pain and patient population characteristics. However, there are still potential challenges, such as the need for large datasets and the risk of bias in training models, which warrant further research.

Verified
Journal Article
Open access
PDF file
RTRicardo A Torres-Guzman
Ricardo A Torres-Guzman
FVFrancisco Rafael Avila Verduzco
Francisco Rafael Avila Verduzco
KMKarla C. Maita
Karla C. Maita
JGJohn Garcia
John Garcia
GVGioacchino D De Sario Velasquez
Gioacchino D De Sario Velasquez
Antonio Jorge ForteAntonio Jorge Forte
Antonio Jorge Forte
Background: The use of bone morphogenic protein and mesenchymal stem cells has shown promise in promoting bone regeneration in calvarial defects. However, a systematic review of the available literature is needed to evaluate the efficacy of this approach. Methods: We comprehensively searched electronic databases using MeSH terms related to skull defects, bone marrow mesenchymal stem cells, and bone morphogenic proteins. Eligible studies included animal studies that used BMP therapy and mesenchymal stem cells to promote bone regeneration in calvarial defects. Reviews, conference articles, book chapters, and non-English language studies were excluded. Two independent investigators conducted the search and data extraction. Results: Twenty-three studies published between 2010 and 2022 met our inclusion criteria after a full-text review of the forty-five records found in the search. Eight of the 23 studies used mice as models, while 15 used rats. The most common mesenchymal stem cell was bone marrow-derived, followed by adipose-derived. BMP-2 was the most popular. Stem cells were embedded in Scaffold (13), Transduction (7), and Transfection (3), and they were delivered BMP to cells. Each treatment used 2 × 104–1 × 107 mesenchymal stem cells, averaging 2.26 × 106. Most BMP-transduced MSC studies used lentivirus. Conclusions: This systematic review examined BMP and MSC synergy in biomaterial scaffolds or alone. BMP therapy and mesenchymal stem cells in calvarial defects, alone, or with a scaffold regenerated bone. This method treats skull defects in clinical trials. The best scaffold material, therapeutic dosage, administration method, and long-term side effects need further study.

7 December 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
RTRicardo A Torres-Guzman
Ricardo A Torres-Guzman
FVFrancisco Rafael Avila Verduzco
Francisco Rafael Avila Verduzco
KMKarla Maita
Karla Maita
JGJohn Garcia
John Garcia
GVGioacchino D De Sario Velasquez
Gioacchino D De Sario Velasquez
Antonio Jorge ForteAntonio Jorge Forte
Antonio Jorge Forte
Background: Despite numerous measures used to prevent pressure ulcers, their growing prevalence in recent years is expected to continue as the population ages. This review aims to report the outcomes of the regenerative potential of MSCs in treating pressure ulcers, assessing the effectiveness of MSCs in treating pressure ulcers. Methods: A computerized search for articles on animal models that use MSCs as primary therapy to treat pressure ulcers, published from conception to present, was conducted using PubMed, MEDLINE, Embase, and CINAHL. Our search yielded 52 articles, narrowed to 44 after excluding duplicates. Results: Out of 52 articles collected from four databases, 11 met the inclusion criteria. A total of 11 articles published between 2008 and 2020 met the inclusion criteria. Eight studies were observational descriptive papers in animal models, and three were prospective. Six studies used autologous MSCs, while five used allogenic MSCs. Three studies were conducted in humans, and the remaining eight were conducted in animals. The most common method of cell delivery was an intradermal injection in the margins of the ulcer. All studies reported positive results, including improved wound healing, reduced inflammation, and improved tissue regeneration. Conclusions: MSCs have shown promising results in treating pressure ulcers in animal and clinical trials. The combination of MSCs and scaffold materials has also been studied and found to be effective in wound healing. A standardized human wound model has been proposed further to investigate the efficacy of cell-based therapies for chronic wounds. However, more research is needed to determine the best quantity of cells to apply for pressure ulcers and to ensure the safety and efficacy of these treatments in clinical settings.

1 February 2023 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
MNMaria A. Nieto-Salazar
Maria A. Nieto-Salazar
FVFelipe Velasquez-Botero
Felipe Velasquez-Botero
ATAdriana C. Toro-Velandia
Adriana C. Toro-Velandia
ESEricka A. Saldana-Rodriguez
Ericka A. Saldana-Rodriguez
MRMiguel E. Rodriguez-Rodriguez
Miguel E. Rodriguez-Rodriguez
RSRajan K. Mbbs Sah
Rajan K. Mbbs Sah
Epilepsy is the most common neurological disorder that affects ~1–2% of the global population, leading to presentation in the emergency room. The neuroimaging modalities have an important application in diagnosing new onset unprovoked seizures and epilepsy. This article discusses the various neuroimaging modalities for diagnosing seizures and epilepsy and addresses that the MRI is the investigation of choice, and urgent imaging is more commonly done by computed tomography in patients with new-onset seizures. The goal of the article was to diagnose seizures and epilepsy for early intervention to prevent complications or damage to the brain. MRI detects even small cortical epileptogenic lesions, whereas computed tomography is used in screening, diagnosis, evaluation, and monitoring of the prognosis of seizures in children. Magnetic resonance spectroscopy provides biochemical measurements of reduced N-acetyl aspartate and increased creatinine and choline in dysfunctioning epileptic zones. Volumetric MRI is very sensitive and specific in determining seizures originating in extratemporal and extrahippocampal sites. Even though diffusion tensor magnetic resonance imaging has a limited role, it is used in specific pediatric patient groups with temporal lobe epilepsy. Functional radionuclide imaging modalities (positron emission tomography and single-photon emission computerized tomography) are increasingly significant for the identification of the epileptic region. Furthermore, the authors recommend the use of artificial intelligence and further research on imaging modalities for early diagnosis of seizures and epilepsy.